Patient characteristics and outcomes
| . | Discovery cohort (n = 20) . | Validation cohort (n = 23) . |
|---|---|---|
| Age, median (range), y | 53 (22-74) | 59 (27-79) |
| Sex | ||
| Male | 9 (45) | 10 (43) |
| Female | 11 (55) | 13 (57) |
| Acute leukemia type | ||
| Myeloid (AML) | 16 (80) | 23 (100) |
| Lymphoblastic (ALL) | 4 (20) | 0 |
| Treatment phase | ||
| First induction | 13 (65) | 6 (26) |
| Reinduction/salvage | 7 (35) | 17 (74) |
| Chemotherapy regimen | ||
| 7 + 3 | 9 (45) | 16 (70) |
| Clo/Ara-C | 2 (10) | 7 (30) |
| MEC | 5 (25) | 0 |
| PETHEMA ALL-AR-0349 | 2 (10) | 0 |
| GRAAPH-200550 : | 2 (10) | 0 |
| Total parenteral nutrition | 5 (25) | 9 (39) |
| NF | 19 (95) | 23 (100) |
| No. of new episodes per patient, mean | 1.8 | 1.5 |
| Bloodstream infection by day 28 | 6 (30) | 8 (35) |
| Bacteroides fragilis, n | 0 | 1 |
| Enterobacter cloacae, n | 0 | 1 |
| Enterococcus faecalis, n | 0 | 1 |
| Enterococcus faecium, n | 1 | 4 |
| Staphylococcus aureus, n | 1 | 0 |
| Staphylococcus epidermidis, n | 0 | 1 |
| Staphylococcus haemolyticus, n | 0 | 1 |
| Streptococcus mitis, n | 3 | 2 |
| Streptococcus sanguinis, n | 1 | 0 |
| C difficile infection | 4 (20) | 3 (13) |
| Antibacterial antibiotics by day 28 | ||
| Fluoroquinolones | 18 (90) | 19 (83) |
| Cephalosporins (generation 3+) | 15 (75) | 23 (100) |
| Carbapenems | 3 (15) | 3 (13) |
| Piperacillin-tazobactam | 6 (30) | 15 (65) |
| Metronidazole | 7 (35) | 10 (43) |
| Oral vancomycin | 3 (15) | 3 (13) |
| IV vancomycin | 10 (50) | 17 (74) |
| . | Discovery cohort (n = 20) . | Validation cohort (n = 23) . |
|---|---|---|
| Age, median (range), y | 53 (22-74) | 59 (27-79) |
| Sex | ||
| Male | 9 (45) | 10 (43) |
| Female | 11 (55) | 13 (57) |
| Acute leukemia type | ||
| Myeloid (AML) | 16 (80) | 23 (100) |
| Lymphoblastic (ALL) | 4 (20) | 0 |
| Treatment phase | ||
| First induction | 13 (65) | 6 (26) |
| Reinduction/salvage | 7 (35) | 17 (74) |
| Chemotherapy regimen | ||
| 7 + 3 | 9 (45) | 16 (70) |
| Clo/Ara-C | 2 (10) | 7 (30) |
| MEC | 5 (25) | 0 |
| PETHEMA ALL-AR-0349 | 2 (10) | 0 |
| GRAAPH-200550 : | 2 (10) | 0 |
| Total parenteral nutrition | 5 (25) | 9 (39) |
| NF | 19 (95) | 23 (100) |
| No. of new episodes per patient, mean | 1.8 | 1.5 |
| Bloodstream infection by day 28 | 6 (30) | 8 (35) |
| Bacteroides fragilis, n | 0 | 1 |
| Enterobacter cloacae, n | 0 | 1 |
| Enterococcus faecalis, n | 0 | 1 |
| Enterococcus faecium, n | 1 | 4 |
| Staphylococcus aureus, n | 1 | 0 |
| Staphylococcus epidermidis, n | 0 | 1 |
| Staphylococcus haemolyticus, n | 0 | 1 |
| Streptococcus mitis, n | 3 | 2 |
| Streptococcus sanguinis, n | 1 | 0 |
| C difficile infection | 4 (20) | 3 (13) |
| Antibacterial antibiotics by day 28 | ||
| Fluoroquinolones | 18 (90) | 19 (83) |
| Cephalosporins (generation 3+) | 15 (75) | 23 (100) |
| Carbapenems | 3 (15) | 3 (13) |
| Piperacillin-tazobactam | 6 (30) | 15 (65) |
| Metronidazole | 7 (35) | 10 (43) |
| Oral vancomycin | 3 (15) | 3 (13) |
| IV vancomycin | 10 (50) | 17 (74) |
Unless otherwise noted, data are n (%).
Clo/Ara-C, clofarabine plus cytarabine; MEC, mitoxantrone plus etoposide plus cytarabine; 7 + 3, cytarabine plus anthracycline (daunorubicin or idarubicin) with or without other drugs.